Drugs / Rabbit antithymoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT04784052 Background | Dec 2021 → Dec 2027 expected | Fanconi anemia | Porteus, Matthew, MD | Recruiting | Met primary |
| Phase 1/2 | NCT02407470 Background | Jan 2015 → Jan 2017 | aplastic anemia | Navy General Hospital, Beijing | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabbit Anti-Thymoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784052 ↗ |
| Known as | rATG | “Biological: Rabbit Anti-Thymoglobulin (rATG)” NCT04784052 ↗ |
| Action | Deplete | “with the goals of ablating host repressive T cells.” NCT02407470 ↗ |
| Modality | Protein / enzyme biologic | “rabbit anti-thymocyte globulin” PMID 40696207 ↗ Jul 2025 |
| Route | Intravenous | “Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.” NCT02407470 ↗ |